May 25, 2020
Otsuka Pharmaceutical Co., Ltd.
Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the oral anti-tuberculosis (TB) drug Deltyba® (delamanid) has been approved in Russia. In 2017 Otsuka entered into an agreement granting commercialization rights in Russia and 11 other countries in the region to the R-Pharm Group, based in the Russian Federation.
TB is an airborne, infectious disease, and drug-resistant infection makes treatment longer, more complicated, and lowers the chances of treatment success. The latest global treatment success rates for MDR-TB/Rifampicin-resistant TB (RR-TB) are less than 60 percent.*1
Improving medical care and promoting healthy life spans was a key topic at the Eastern Economic Forum held in Vladivostok, Russia on September 7, 2017, where Japan's Prime Minister Shinzo Abe stated, "In the fight against tuberculosis, Japan and Russia have joined hands."
Deltyba has potent bactericidal activity against Mycobacterium tuberculosis and is the first approved compound from the bicyclic nitro-imidazole derivatives for the treatment of pulmonary MDR-TB in adult patients.*2 It received regulatory approval in China, the European Union, Hong Kong, India, Indonesia, Japan, Kazakhstan, Mongolia, Peru, South Africa, South Korea, Philippines, Turkey, Turkmenistan, and Ukraine. Deltyba is indicated in Russia for use as part of an appropriate combination regimen for pulmonary MDR-TB in adult patients.
- 1World Health Organization. Global tuberculosis report 2019. http://www.who.int/tb/publications/global_report/en/
- 2Matsumoto M, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLOS Med 2006; 3: e466
Information in this news release was current as of the original release date.